ROTIUM Bioresorbable Wick
Commercial- Indications
- Rotator cuff tear
Company intelligence / Profile preview
Atreon's flagship product ROTIUM® Bioresorbable Wick has demonstrated significant clinical benefit in rotator cuff repair with a reduction in cumulative treatment failure rate from ~50% to ~7.1% over an average of 17 months follow-up. Animal studies show increased failure strength and improved bone-tendon integration. The company recently received expanded FDA clearance for broader tendon repairs and launched BioCharge®, a novel onlay scaffold for additional biologic support.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Atreon Orthopedics.